`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
`
` NDA 021344/S-025
`
`
`
`
`
`
`
`
`
`Food and Drug Administration
`
`Silver Spring MD 20993
`
`SUPPLEMENT APPROVAL
`
`
`AstraZeneca Pharmaceuticals LP
`Attention: Karen McCullough, PhD
`Director, Global Regulatory Affairs
`One MedImmune Way
`Gaithersburg, MD 20878
`
`
`Dear Dr. McCullough:
`
`Please refer to your Supplemental New Drug Application (sNDA) dated October 28, 2015,
`received October 28, 2015, submitted under section 505(b) of the Federal Food, Drug, and
`Cosmetic Act (FDCA) for FASLODEX® (fulvestrant) Solution for Injection, 50 mg/ml.
`
`This “Prior Approval” supplemental new drug application provides for the United States
`Prescribing Information (USPI) Pregnancy and Lactation Labeling Rule (PLLR) conversion.
`
`APPROVAL & LABELING
`
`We have completed our review of this supplemental application, as amended. It is approved,
`effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling
`
`text.
`
`We note that your October 28, 2015, submission includes final printed labeling (FPL) for your
`package insert and patient package insert. We have not reviewed this FPL. You are responsible
`for assuring that the wording in this printed labeling is identical to that of the approved content
`of labeling in the structured product labeling (SPL) format.
`
`CONTENT OF LABELING
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
`automated drug registration and listing system (eLIST), as described at
`http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content
`of labeling must be identical to the enclosed labeling (text for the package insert, text for the
`patient package insert, with the addition of any labeling changes in pending “Changes Being
`Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed
`labeling.
`
`
`Reference ID: 3894565
`
`
`
`NDA 021344/S-025
`Page 2
`
`
`Information on submitting SPL files using eList may be found in the guidance for industry titled
`“SPL Standard for Content of Labeling Technical Qs and As at
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U
`CM072392.pdf.
`
`
`The SPL will be accessible from publicly available labeling repositories.
`
`Also within 14 days, amend all pending supplemental applications that includes labeling changes
`for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
`with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
`changes approved in this supplemental application, as well as annual reportable changes and
`annotate each change. To facilitate review of your submission, provide a highlighted or marked-
`up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
`should provide appropriate annotations, including supplement number(s) and annual report
`date(s).
`
`
`REQUIRED PEDIATRIC ASSESSMENTS
`
`Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new
`active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of
`administration are required to contain an assessment of the safety and effectiveness of the
`product for the claimed indication(s) in pediatric patients unless this requirement is waived,
`deferred, or inapplicable.
`
`Because none of these criteria apply to your application, you are exempt from this requirement.
`
`REPORTING REQUIREMENTS
`
`
`We remind you that you must comply with reporting requirements for an approved NDA
`(21 CFR 314.80 and 314.81).
`
`If you have any questions, call Charlene Wheeler, MSHS, Senior Regulatory Project Manager, at
`(301) 796-1141.
`
`
`Sincerely,
`
`{See appended electronic signature page}
`
`
`Geoffrey Kim, MD
`Director
`
`Division of Oncology Products 1
`Office of Hematology and Oncology Products
`Center for Drug Evaluation and Research
`
`ENCLOSURE(S):
`Content of Labeling
`
`
`Reference ID: 3894565
`
`
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`GEOFFREY S KIM
`03/01/2016
`
`Reference ID: 3894565
`
`